儿童特应性皮炎患者2型炎症性疾病的患病率:真实世界证据
基于美国IBM MarketScan 2013-2017理赔数据库,将244,776例儿童特应性皮炎(AD)患者与非AD患者1:1匹配,评估指数日期后12个月内结膜炎、鼻炎、荨麻疹、哮喘、嗜酸性食管炎和慢性鼻窦炎/鼻息肉的患病率,以及0-2岁患者中其他2型炎症性疾病的发病率。AD患者中2型炎症性疾病的患病率和发病率均更高,哮喘、嗜酸性食管炎、荨麻疹和鼻炎的患病率增加一倍以上,且随AD严重程度增加。
要点
- AD患者中哮喘、嗜酸性食管炎、荨麻疹和鼻炎的患病率较非AD患者增加一倍以上。
- 2型炎症性疾病的患病率随AD严重程度增加而升高。
- 0-2岁AD患者中其他2型炎症性疾病的发病率也更高。
核心结论
- 儿童AD患者中2型炎症性疾病负担 substantial,凸显优化AD及其众多相关疾病管理的必要性。
研究设计与样本
- 基于美国IBM MarketScan 2013-2017理赔数据库的真实世界证据研究,将儿童AD患者与非AD患者按1:1匹配。
- 共纳入244,776例AD患者及匹配的非AD患者。
- 在指数日期后12个月评估结膜炎、鼻炎、荨麻疹、哮喘、嗜酸性食管炎和慢性鼻窦炎/鼻息肉的患病率;在0-2岁患者中评估指数日期后其他2型炎症性疾病的发病率。
主要发现
- AD患者中2型炎症性疾病的患病率和发病率均高于非AD患者。
- 总体而言,哮喘、嗜酸性食管炎、荨麻疹和鼻炎的患病率增加一倍以上,且随AD严重程度增加。
局限性
- AD识别基于账单诊断。
- 观察期仅12个月。
- 研究仅限于商业保险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with atopic dermatitis (AD) are considered at increased risk of developing other type 2 inflammatory diseases. However, real-world evidence based on large commercially insured pediatric populations in the United States is scarce. OBJECTIVE: To use a large claims database (IBM MarketScan 2013-2017) in the United States to assess prevalence and incidence of type 2 inflammatory diseases in pediatric patients with AD. METHODS: Pediatric patients with AD were matched 1:1 to patients without AD. Prevalence was assessed for conjunctivitis, rhinitis, urticaria, asthma, eosinophilic esophagitis, and chronic rhinosinusitis/nasal polyps at the 12 months' post-index date (the first AD diagnosis date for patients with AD; a randomly selected outpatient visit for control patients). The incidence of other type 2 inflammatory diseases post-index was assessed among patients 0-2 years of age. RESULTS: A total of 244,776 AD and matched non-AD patients were selected. The prevalence and incidence of type 2 inflammatory diseases were higher among patients with AD. Overall, the prevalence more than doubled for asthma, eosinophilic esophagitis, urticaria, and rhinitis, and increased with AD severity. LIMITATIONS: AD identification was based on billing diagnoses; the observation period was only 12 months; and the study was limited to commercially insured patients. CONCLUSION: The burden of type 2 inflammatory diseases in pediatric patients with AD is substantial, highlighting the need to optimize management of AD and its numerous associated morbidities.
引用
- Paller AS, Mina-Osorio P, Vekeman F, et al. Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. J Am Acad Dermatol. 2021. PMID: 34756933. doi:10.1016/j.jaad.2021.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。